Anti-convulsants and brain aldehyde metabolism: inhibitory characteristics of ox brain aldehyde reductase.
D000429:Alcohol Oxidoreductases / Q000037:antagonists & inhibitors*; D000449:Aldehyde Reductase / Q000037:antagonists & inhibitors; D000447:Aldehydes / Q000378:metabolism*; D000818:Animals; D000927:Anticonvulsants / Q000494:pharmacology*; D044482:Benzeneacetamides; D001921:Brain / Q000187:drug effects* / Q000378:metabolism; D002220:Carbamazepine / Q000494:pharmacology; D002417:Cattle; D066298:In Vitro Techniques; D007527:Isoenzymes / Q000037:antagonists & inhibitors; D008297:Male; D010648:Phenylacetates / Q000494:pharmacology; D014508:Urea / Q000031:analogs & derivatives / Q000494:pharmacology; D014635:Valproic Acid / Q000031:analogs & derivatives / Q000494:pharmacology
D000447:Aldehydes; D000927:Anticonvulsants; D044482:Benzeneacetamides; D007527:Isoenzymes; D010648:Phenylacetates; D002220:Carbamazepine; D014635:Valproic Acid; D014508:Urea; D000429:Alcohol Oxidoreductases; C019642:alcohol dehydrogenase (NADP+); D000449:Aldehyde Reductase; C005396:phenacemide